Rossari Biotech

June 06, 2023 07:13 AM IST

Trade Spotlight | How should you trade in Rossari Biotech, NLC India, eClerx Services today

eClerx Services has also formed strong bullish candlestick pattern on the daily charts with above average volumes as the stock jumped more than 6 percent to Rs 1,715, the highest closing level since January 20, 2022. The stock has seen a breakout of last four-day consolidation.

Rossari Consolidated March 2023 Net Sales at Rs 406.47 crore, down 7.4% Y-o-Y

Rossari Standalone March 2023 Net Sales at Rs 263.64 crore, up 0.76% Y-o-Y

Channel checks by ICICI Securities reflect mixed price, volume trends for Specialty Chemcials cos in January

ICICI Securities has a "buy" rating on Gujarat Fluorochemicals, Archean Chemical, Tatva Chintan, EPL, Chemplast Sanmar, PCBL in the specialty chemicals basket, along with a "hold" call for industry leader SRF.

Buy Rossari Biotech; target of Rs 974: KR Choksey

KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 974 in its research report dated February 10, 2023.

Buy Rossari Biotech; target of Rs 1095: YES Securities

YES Securities is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1095 in its research report dated February 07, 2023.

Rossari Standalone December 2022 Net Sales at Rs 236.90 crore, down 11.82% Y-o-Y

Rossari Consolidated December 2022 Net Sales at Rs 389.27 crore, down 9.14% Y-o-Y

Rossari Standalone September 2022 Net Sales at Rs 240.90 crore, down 28.86% Y-o-Y

Rossari Consolidated September 2022 Net Sales at Rs 425.44 crore, up 10.64% Y-o-Y

Top 10 trading ideas for next 3-4 weeks as volatility rules Dalal Street

Healthcare Global Enterprises has broken out from the horizontal channel on the weekly charts. Price breakout is accompanied by jump in volumes. It is placed above all important moving averages, which indicates bullish trend on all time frames.

Top 10 trading ideas by experts for next 3-4 weeks as bears retain the reins

Given the subdued environment, the index may touch its August lows of around 17,150 and if that gets broken, then falling below psychological 17,000 mark can't be ruled out in coming sessions, with hurdle on the upside at 17,700-17,800 levels

Buy Rossari Biotech; target of Rs 1252: KR Choksey

KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1252 in its research report dated August 10, 2022.

Rossari Consolidated June 2022 Net Sales at Rs 434.71 crore, up 88.1% Y-o-Y

Rossari Standalone June 2022 Net Sales at Rs 233.74 crore, up 14.61% Y-o-Y

Trade Spotlight | What should you do with Rossari Biotech, Devyani International, Greenply Industries on Thursday?

"What a great setup we are having at Greenply Industries -- precise bullish BAT pattern which got completed at 0.886 ratio on the daily chart with N-wave formation near the potential reversal zone of Rs 170-175."

Buy Rossari Biotech; target of Rs 1355: YES Securities

YES Securities is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1355 in its research report date May 25, 2022.

Buy Rossari Biotech; target of Rs 1252: KR Choksey

KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1252 in its research report dated May 24, 2022.

Rossari Consolidated March 2022 Net Sales at Rs 438.93 crore, up 101.14% Y-o-Y

Rossari Standalone March 2022 Net Sales at Rs 261.64 crore, up 29.86% Y-o-Y

Buy Rossari Biotech; target of Rs 1456: KR Choksey

KR Choksey is bullish on Rossari Biotech has recommended buy rating on the stock with a target price of Rs 1456 in its research report dated March 28, 2022.

Rossari Consolidated December 2021 Net Sales at Rs 428.42 crore, up 104.02% Y-o-Y

Rossari Consolidated December 2021 Net Sales at Rs 428.42 crore, up 104.02% Y-o-Y

Rossari Standalone December 2021 Net Sales at Rs 268.64 crore, up 30.56% Y-o-Y

Rossari Biotech hikes prices, sees 50% jump in revenue, profit this fiscal

The board has set us a target to more than double our revenue and profit from the FY'20 levels by FY'23, both through organic as well as inorganic routes.